Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yogliptin Monotherapy in Chinese Patients with Type 2 Diabetes
NCT05318326Phase 3Unknown
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of yogliptin in type 2 diabetes mellitus (T2DM), sponsored by Chengdu Easton Biopharmaceuticals Co., Ltd.. Status: unknown.
02
Drugs
yogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05318326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318326.